▁Introduction 7.8203125
: 1.9072265625
<0x0A> 6.52734375
M 4.66796875
el 4.48828125
an 2.740234375
oma 0.340087890625
▁is 0.42236328125
▁an 3.2578125
▁ag 0.87060546875
gress 0.00194549560546875
ive 0.0060272216796875
▁form 1.3701171875
▁of 0.00377655029296875
▁skin 0.1378173828125
▁cancer 0.006801605224609375
▁that 0.92041015625
▁can 1.5283203125
▁met 3.859375
ast 0.003696441650390625
as 0.01110076904296875
ize 0.034332275390625
▁rapidly 3.66796875
▁if 2.734375
▁left 1.1259765625
▁un 0.0633544921875
tre 0.05853271484375
ated 0.00013458728790283203
. 0.109130859375
▁Over 5.4453125
▁the 0.66064453125
▁years 2.138671875
, 0.1156005859375
▁adv 4.24609375
anc 1.1337890625
ements 7.963180541992188e-05
▁in 0.138427734375
▁medical 2.58984375
▁science 2.068359375
▁have 0.29833984375
▁led 1.40625
▁to 0.0124053955078125
▁the 0.9931640625
▁development 0.244873046875
▁of 0.010467529296875
▁ground 6.99609375
bre 0.4111328125
aking 1.7881393432617188e-05
▁treat 0.94140625
ments 0.00018012523651123047
, 2.34375
▁not 6.9921875
ably 0.37646484375
▁imm 1.1123046875
une 2.759765625
▁check 0.1484375
point 0.005451202392578125
▁in 0.1328125
hib 7.104873657226562e-05
itors 0.06781005859375
▁and 2.904296875
▁adj 4.80859375
uv 0.0200653076171875
ant 0.0298004150390625
▁ther 0.46337890625
ap 0.85302734375
ies 0.00018894672393798828
. 0.521484375
▁These 1.7646484375
▁novel 3.744140625
▁approaches 1.794921875
▁have 0.410888671875
▁shown 2.794921875
▁great 2.75
▁potential 2.1875
▁in 0.09307861328125
▁ach 6.02734375
ieving 2.3245811462402344e-05
▁long 1.67578125
- 0.0062255859375
term 0.1297607421875
▁rem 0.798828125
ission 0.11993408203125
▁and 0.88134765625
▁impro 1.3759765625
ving 0.0008754730224609375
▁surv 1.642578125
ival 0.00383758544921875
▁rates 0.289794921875
▁for 1.2880859375
▁patients 0.60888671875
▁at 6.3671875
▁different 3.84375
▁stages 0.05657958984375
▁of 0.07696533203125
▁mel 0.85498046875
an 5.5909156799316406e-05
oma 0.0006780624389648438
. 0.2144775390625
▁This 2.47265625
▁ess 3.689453125
ay 0.0003185272216796875
▁a 1.8046875
ims 2.0623207092285156e-05
▁to 0.0059661865234375
▁discuss 2.302734375
▁the 0.31201171875
▁adv 4.9921875
anc 0.274658203125
ements 4.184246063232422e-05
▁in 0.375732421875
▁these 4.49609375
▁treat 0.9853515625
ments 2.8967857360839844e-05
, 1.123046875
▁their 0.85791015625
▁imp 3.681640625
lications 0.006237030029296875
▁for 0.59716796875
▁patients 1.470703125
, 0.341552734375
▁and 0.04205322265625
▁illustrate 12.6640625
▁their 1.373046875
▁impact 2.169921875
▁on 0.07867431640625
▁surv 3.064453125
ival 0.033966064453125
▁rates 0.2235107421875
▁through 5.00390625
▁the 2.857421875
▁case 3.072265625
▁of 0.72998046875
▁Mr 3.91796875
. 0.0743408203125
▁B 3.982421875
. 0.84716796875
<0x0A> 0.1566162109375
Ad 1.2119140625
van 1.0185546875
c 0.0202178955078125
ements 0.0002651214599609375
▁in 0.0129241943359375
▁Mel 1.8740234375
an 7.87973403930664e-05
oma 0.0002570152282714844
▁Tre 0.07489013671875
at 4.208087921142578e-05
ment 0.6181640625
: 0.2266845703125
<0x0A> 0.0885009765625
Im 0.88818359375
m 0.1728515625
une 0.0053558349609375
▁check 0.342529296875
point 0.002178192138671875
▁in 0.005771636962890625
hib 8.821487426757812e-06
itors 0.0081024169921875
▁such 4.5546875
▁as 0.0007166862487792969
▁p 1.8759765625
emb 0.0034847259521484375
rol 0.00039267539978027344
iz 0.0005497932434082031
um 0.0005054473876953125
ab 0.00014460086822509766
▁and 0.837890625
▁n 0.33837890625
iv 0.00036072731018066406
ol 0.0008835792541503906
um 0.0010471343994140625
ab 0.00012314319610595703
▁have 0.4091796875
▁revolution 0.6220703125
ized 0.0030078887939453125
▁mel 1.8564453125
an 2.4437904357910156e-05
oma 9.500980377197266e-05
▁treatment 0.055023193359375
. 0.83837890625
▁These 0.1693115234375
▁dru 0.238037109375
gs 3.0994415283203125e-06
▁work 0.66845703125
▁by 0.0037899017333984375
▁blocking 0.5546875
▁the 0.287109375
▁interaction 1.5625
▁between 0.05029296875
▁cancer 4.65234375
▁cells 0.02105712890625
▁and 0.0028018951416015625
▁imm 0.7744140625
une 0.018890380859375
▁in 5.9375
hib 0.0150909423828125
itory 0.0994873046875
▁mole 0.8251953125
cules 0.001972198486328125
, 0.1973876953125
▁thus 2.68359375
▁activ 2.39453125
ating 0.00010716915130615234
▁the 0.07440185546875
▁imm 0.17138671875
une 8.094310760498047e-05
▁system 0.0631103515625
▁to 0.432861328125
▁recognize 1.1552734375
▁and 0.011688232421875
▁eliminate 1.8955078125
▁cancer 0.52685546875
▁cells 0.0927734375
. 0.119140625
▁They 4.171875
▁have 0.200439453125
▁demonstrated 2.7265625
▁remarkable 1.8935546875
▁success 1.4208984375
▁in 0.05084228515625
▁ach 2.287109375
ieving 0.0008711814880371094
▁dur 3.08984375
able 0.00021004676818847656
▁responses 1.615234375
▁and 1.234375
▁prolong 1.541015625
ed 0.9853515625
▁surv 0.66357421875
ival 0.00212860107421875
▁rates 1.3203125
▁in 0.72314453125
▁met 3.763671875
ast 0.00011098384857177734
atic 0.001453399658203125
▁mel 0.080322265625
an 1.5974044799804688e-05
oma 0.0012340545654296875
▁patients 0.43408203125
. 0.498046875
<0x0A> 0.86083984375
Add 4.1640625
itionally 0.0084686279296875
, 0.0001493692398071289
▁adj 0.587890625
uv 0.00019049644470214844
ant 0.0004379749298095703
▁ther 0.04962158203125
ap 0.382080078125
ies 1.6689300537109375e-06
, 1.982421875
▁such 0.349853515625
▁as 6.437301635742188e-05
▁inter 2.369140625
fer 0.336669921875
on 0.006000518798828125
▁ther 4.15234375
apy 0.0155487060546875
, 0.6904296875
▁target 3.142578125
ed 1.966796875
▁ther 0.0989990234375
apy 0.6474609375
, 0.135986328125
▁and 0.0946044921875
▁cancer 7.1328125
▁v 0.12188720703125
acc 5.841255187988281e-05
ines 0.053497314453125
, 0.042022705078125
▁have 0.359375
▁played 5.15234375
▁a 0.1383056640625
▁p 4.08203125
iv 3.933906555175781e-06
otal 3.5762786865234375e-07
▁role 0.0003123283386230469
▁in 0.0007443428039550781
▁reducing 1.5615234375
▁disease 4.11328125
▁rec 0.333251953125
urrence 0.01248931884765625
▁and 0.564453125
▁impro 0.155517578125
ving 1.71661376953125e-05
▁overall 1.330078125
▁surv 0.09564208984375
ival 0.00025963783264160156
▁rates 0.35595703125
▁post 5.5
- 0.0352783203125
s 0.269287109375
urg 2.372264862060547e-05
ery 0.10980224609375
. 0.07379150390625
▁These 1.0703125
▁ther 0.775390625
ap 0.0001398324966430664
ies 5.960464477539062e-07
▁are 2.35546875
▁often 2.837890625
▁tail 5.8359375
ored 0.0022029876708984375
▁to 0.07525634765625
▁the 0.66015625
▁specific 0.9912109375
▁mole 1.9384765625
cular 0.0015306472778320312
▁characteristics 1.8564453125
▁of 0.0132598876953125
▁mel 5.00390625
an 3.4689903259277344e-05
oma 0.015594482421875
, 1.0439453125
▁ens 2.71875
uring 2.384185791015625e-06
▁a 3.39453125
▁patient 7.1796875
- 0.58154296875
center 1.05859375
ed 0.0001252889633178711
▁approach 0.048065185546875
. 2.34375
<0x0A> 0.0841064453125
Imp 1.5380859375
lications 0.09869384765625
▁for 0.1103515625
▁Pat 0.031219482421875
ients 0.00738525390625
▁at 7.53125
▁D 0.0660400390625
ifferent 0.00045609474182128906
▁St 0.0083160400390625
ages 2.2172927856445312e-05
: 1.21875
<0x0A> 0.0045623779296875
For 2.06640625
▁patients 0.09539794921875
▁with 0.94091796875
▁early 0.7353515625
- 0.1466064453125
stage 0.0012788772583007812
▁mel 0.036651611328125
an 2.1338462829589844e-05
oma 0.004360198974609375
, 0.051513671875
▁imm 3.384765625
une 0.7763671875
▁check 0.0236053466796875
point 0.0046234130859375
▁in 0.008697509765625
hib 1.7881393432617188e-06
itors 0.01236724853515625
▁have 1.7177734375
▁shown 1.07421875
▁prom 1.2119140625
ising 4.2319297790527344e-05
▁out 3.376953125
comes 2.193450927734375e-05
▁for 4.94921875
▁reducing 3.38671875
▁the 0.43212890625
▁risk 0.051971435546875
▁of 0.0008831024169921875
▁rec 0.74365234375
urrence 0.013916015625
. 0.78369140625
▁Studies 3.7109375
▁have 0.0714111328125
▁shown 0.984375
▁that 0.039642333984375
▁patients 1.8935546875
▁with 1.1943359375
▁Stage 3.69140625
▁III 2.298828125
▁mel 0.87646484375
an 8.857250213623047e-05
oma 0.0030536651611328125
▁who 0.41455078125
▁receive 0.998046875
▁adj 1.10546875
uv 0.0016613006591796875
ant 7.784366607666016e-05
▁ther 0.80078125
apy 0.10174560546875
▁with 1.5810546875
▁imm 1.251953125
une 0.07684326171875
▁check 0.004749298095703125
point 0.004123687744140625
▁in 0.00481414794921875
hib 1.430511474609375e-06
itors 0.00650787353515625
▁experienced 6.5078125
▁significantly 2.095703125
▁better 2.591796875
▁rec 4.27734375
urrence 0.00030040740966796875
- 0.141357421875
free 0.000736236572265625
▁surv 0.07861328125
ival 0.0004057884216308594
▁compared 2.396484375
▁to 0.02386474609375
▁traditional 6.9609375
▁treat 2.26953125
ments 2.8848648071289062e-05
. 0.462646484375
▁This 3.080078125
▁implies 3.90625
▁that 0.031097412109375
▁these 1.67578125
▁ther 1.54296875
ap 0.00044727325439453125
ies 1.5497207641601562e-06
▁can 1.044921875
▁potentially 2.603515625
▁convert 9.1328125
▁a 2.439453125
▁dead 3.677734375
ly 0.0122833251953125
▁disease 0.5078125
▁into 0.08929443359375
▁a 0.08221435546875
▁manage 1.4853515625
able 3.7789344787597656e-05
▁condition 1.1552734375
▁in 5.046875
▁the 0.9384765625
▁long 0.63037109375
▁term 0.66357421875
. 0.078857421875
<0x0A> 0.0386962890625
In 2.65234375
▁patients 1.845703125
▁with 0.0281829833984375
▁advanced 0.7734375
- 1.3740234375
stage 0.001224517822265625
▁mel 0.09112548828125
an 3.159046173095703e-05
oma 0.0013494491577148438
, 0.044891357421875
▁imm 0.58642578125
une 0.03155517578125
▁check 0.00464630126953125
point 0.0018138885498046875
▁in 0.0035724639892578125
hib 4.0531158447265625e-06
itors 0.006656646728515625
▁have 0.42041015625
▁provided 4.328125
▁previously 7.91015625
▁un 0.046051025390625
seen 2.166015625
▁levels 2.04296875
▁of 0.00022137165069580078
▁control 3.671875
▁over 0.5537109375
▁the 0.276611328125
▁disease 0.0745849609375
. 0.2529296875
▁The 3.09375
▁use 3.107421875
▁of 0.000186920166015625
▁p 2.880859375
emb 0.01175689697265625
rol 0.00011169910430908203
iz 8.475780487060547e-05
um 0.0002918243408203125
ab 4.6253204345703125e-05
▁has 1.7705078125
▁yield 5.0234375
ed 0.0001475811004638672
▁remarkable 2.267578125
▁results 0.60302734375
, 0.5966796875
▁with 0.197265625
▁studies 4.5703125
▁finding 4.87890625
▁that 0.2423095703125
▁patients 1.716796875
▁achieved 4.3828125
▁higher 4.93359375
▁objective 3.513671875
▁response 0.1492919921875
▁rates 0.00984954833984375
▁and 0.61376953125
▁longer 0.9560546875
▁pro 0.7490234375
gression 2.6226043701171875e-06
- 0.0012483596801757812
free 0.0002351999282836914
▁surv 0.025543212890625
ival 0.0008077621459960938
▁compared 0.80859375
▁to 0.01197052001953125
▁conventional 3.021484375
▁chem 1.841796875
other 0.0017023086547851562
apy 0.09613037109375
. 0.225341796875
▁This 1.833984375
▁offers 5.88671875
▁renew 4.2265625
ed 4.8041343688964844e-05
▁hope 0.005828857421875
▁and 3.720703125
▁prolong 4.42578125
ed 0.221435546875
▁surv 0.298583984375
ival 0.004596710205078125
▁for 0.92431640625
▁individuals 3.515625
▁facing 2.58203125
▁advanced 1.52734375
▁mel 1.04296875
an 3.5762786865234375e-05
oma 0.0009279251098632812
. 0.11590576171875
<0x0A> 0.01151275634765625
The 2.25390625
▁Case 0.7021484375
▁of 0.007801055908203125
▁Mr 0.0018301010131835938
. 0.003795623779296875
▁B 0.0018329620361328125
: 0.06549072265625
<0x0A> 0.045166015625
To 4.39453125
▁illustrate 0.50634765625
▁the 0.046600341796875
▁impact 0.29345703125
▁of 0.0298309326171875
▁imm 2.212890625
une 0.02667236328125
▁check 0.004543304443359375
point 0.0018358230590820312
▁in 0.003383636474609375
hib 3.4570693969726562e-06
itors 0.026153564453125
▁in 2.908203125
▁mel 1.2158203125
an 3.933906555175781e-05
oma 9.953975677490234e-05
▁treatment 0.1260986328125
, 0.0197906494140625
▁we 1.2734375
▁can 1.0859375
▁examine 2.080078125
▁Mr 2.916015625
. 0.0019521713256835938
▁B 0.003154754638671875
' 1.322265625
s 0.00034117698669433594
▁case 0.29296875
. 0.135009765625
▁Mr 0.25634765625
. 0.0029697418212890625
▁B 0.001743316650390625
▁was 0.79931640625
▁diagn 0.302490234375
osed 4.76837158203125e-06
▁with 0.0032253265380859375
▁met 1.9736328125
ast 0.00013625621795654297
atic 0.0012836456298828125
▁mel 0.052947998046875
an 2.8967857360839844e-05
oma 3.0040740966796875e-05
▁and 1.521484375
▁was 1.6591796875
▁initially 1.6494140625
▁respond 8.15625
ing 0.00402069091796875
▁poor 4.875
ly 4.076957702636719e-05
▁to 0.0034198760986328125
▁traditional 1.4541015625
▁treat 0.81396484375
ments 1.9788742065429688e-05
. 0.253173828125
▁However 0.82421875
, 0.0001596212387084961
▁upon 2.400390625
▁starting 2.671875
▁p 1.4267578125
emb 0.0007052421569824219
rol 5.245208740234375e-05
iz 3.409385681152344e-05
um 0.00018477439880371094
ab 4.7326087951660156e-05
▁ther 1.1796875
apy 0.0001093149185180664
, 0.029754638671875
▁his 1.1884765625
▁tum 0.814453125
or 0.95263671875
▁re 5.25390625
gress 0.0169830322265625
ions 6.22265625
▁were 0.994140625
▁observed 2.83203125
, 0.92919921875
▁leading 3.439453125
▁to 0.00977325439453125
▁a 1.048828125
▁dur 2.638671875
able 0.00043582916259765625
▁response 0.5703125
▁with 3.087890625
▁no 1.2939453125
▁disease 2.609375
▁pro 0.15283203125
gression 8.499622344970703e-05
. 1.4658203125
<0x0A> 2.716796875
This 0.7998046875
▁case 0.489013671875
▁exempl 3.248046875
ifies 0.00400543212890625
▁the 0.15234375
▁potential 1.173828125
▁of 0.126708984375
▁imm 0.139892578125
une 0.0173492431640625
▁check 0.00518035888671875
point 0.0022106170654296875
▁in 0.00409698486328125
hib 1.3113021850585938e-06
itors 0.01120758056640625
▁in 0.326416015625
▁ach 0.88720703125
ieving 6.222724914550781e-05
▁long 0.2042236328125
- 0.0009455680847167969
term 0.041290283203125
▁rem 0.0977783203125
ission 0.01739501953125
▁for 2.103515625
▁patients 0.53369140625
▁with 0.1865234375
▁advanced 0.515625
▁mel 0.34912109375
an 2.574920654296875e-05
oma 0.00040435791015625
. 0.041168212890625
▁Mr 1.869140625
. 0.00260162353515625
▁B 0.000926971435546875
' 0.1683349609375
s 0.00010573863983154297
▁experience 1.751953125
▁highlight 0.9072265625
s 0.00106048583984375
▁how 3.3203125
▁target 3.85546875
ed 0.07757568359375
▁ther 0.50244140625
ap 0.1903076171875
ies 4.5299530029296875e-06
▁can 0.257568359375
▁effectively 3.220703125
▁halt 4.71875
▁disease 1.5224609375
▁pro 0.00927734375
gression 0.00012731552124023438
, 1.4052734375
▁extending 4.0234375
▁surv 1.078125
ival 0.0026187896728515625
▁and 1.8583984375
▁impro 0.146240234375
ving 1.7642974853515625e-05
▁the 2.142578125
▁quality 0.380615234375
▁of 0.00021839141845703125
▁life 0.0025997161865234375
▁for 0.16357421875
▁patients 0.71630859375
▁facing 3.021484375
▁a 1.716796875
▁previously 4.16796875
▁ble 5.77734375
ak 0.00021922588348388672
▁pro 0.30908203125
gn 4.291534423828125e-06
osis 0.00014293193817138672
. 0.005336761474609375
<0x0A> 0.034332275390625
Con 2.89453125
clusion 0.18701171875
: 0.19482421875
<0x0A> 6.6875
The 2.025390625
▁adv 0.22998046875
anc 0.043853759765625
ements 1.1801719665527344e-05
▁in 0.0125885009765625
▁mel 0.2193603515625
an 2.1457672119140625e-05
oma 1.9431114196777344e-05
▁treatment 0.08258056640625
▁through 3.162109375
▁imm 0.38134765625
une 0.00933837890625
▁check 0.0010089874267578125
point 0.0014600753784179688
▁in 0.0010442733764648438
hib 3.5762786865234375e-07
itors 0.003681182861328125
▁and 0.052978515625
▁adj 0.0308990478515625
uv 0.00048470497131347656
ant 0.00028824806213378906
▁ther 0.0009946823120117188
ap 0.00904083251953125
ies 6.794929504394531e-06
▁have 0.20947265625
▁significantly 2.099609375
▁transformed 2.353515625
▁the 0.10784912109375
▁pro 1.787109375
gn 0.0008001327514648438
osis 0.007354736328125
▁and 2.724609375
▁quality 1.9560546875
▁of 0.0011310577392578125
▁life 0.01015472412109375
▁for 0.1160888671875
▁patients 0.431640625
▁at 2.59765625
▁different 0.186767578125
▁stages 0.0028896331787109375
. 1.80859375
▁Through 5.16015625
▁extensive 7.03125
▁research 0.186279296875
▁and 0.293212890625
▁evidence 4.65234375
, 2.58203125
▁it 1.4951171875
▁is 0.2379150390625
▁evident 0.61865234375
▁that 0.0017595291137695312
▁these 0.0953369140625
▁treat 0.99365234375
ments 8.225440979003906e-06
▁offer 1.72265625
▁the 3.953125
▁potential 0.4287109375
▁for 1.099609375
▁long 0.779296875
- 0.000667572021484375
term 0.0308837890625
▁rem 0.07952880859375
ission 0.00543212890625
, 1.580078125
▁particularly 5.9609375
▁when 4.84375
▁combined 0.85302734375
▁with 0.0257415771484375
▁personal 4.08203125
ized 0.0009927749633789062
▁adj 5.58203125
uv 0.0006723403930664062
ant 0.0020618438720703125
▁ther 0.053253173828125
ap 0.2015380859375
ies 8.225440979003906e-06
. 0.1708984375
▁As 1.8623046875
▁demonstrated 6.1953125
▁by 0.77734375
▁Mr 0.67626953125
. 0.0011844635009765625
▁B 0.0014276504516601562
' 0.038360595703125
s 0.00010037422180175781
▁case 0.226318359375
, 0.0191802978515625
▁these 0.6953125
▁adv 2.611328125
anc 0.04730224609375
ements 8.344650268554688e-06
▁bring 5.18359375
▁hope 0.361328125
▁for 3.029296875
▁patients 1.4501953125
▁facing 0.59765625
▁advanced 1.0595703125
▁mel 0.253173828125
an 1.5974044799804688e-05
oma 0.0003757476806640625
, 0.689453125
▁prom 5.21875
ising 0.86181640625
▁increased 4.89453125
▁surv 0.2191162109375
ival 0.004642486572265625
▁rates 0.251220703125
▁and 0.10662841796875
▁improved 0.282958984375
▁overall 3.005859375
▁out 1.1640625
comes 0.005077362060546875
. 0.034912109375
▁Cont 6.859375
in 0.16064453125
ued 0.0012388229370117188
▁research 0.278076171875
▁and 0.3251953125
▁innov 1.41015625
ation 0.0863037109375
▁in 0.296630859375
▁this 0.8837890625
▁field 0.206298828125
▁hold 2.53515625
▁promise 2.39453125
▁for 0.11163330078125
▁further 1.1455078125
▁adv 1.212890625
anc 0.0745849609375
ements 1.2755393981933594e-05
, 2.349609375
▁offering 2.830078125
▁hope 2.501953125
▁to 1.326171875
▁count 2.9375
less 4.756450653076172e-05
▁individuals 0.176025390625
▁batt 2.373046875
ling 0.0002288818359375
▁this 0.2440185546875
▁ag 1.4765625
gress 6.0439109802246094e-05
ive 1.7523765563964844e-05
▁form 0.7294921875
▁of 0.0003566741943359375
▁skin 1.26953125
▁cancer 0.00020384788513183594
. 0.01412200927734375
